We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale

Law360 (May 6, 2019, 9:45 PM EDT) -- After a last-minute negotiating flurry, biotech firm MabVax Therapeutics Holdings secured tentative approval Monday for the $3.7 million sale of many of its remaining assets while retaining litigation rights against alleged...
To view the full article, register now.